Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC increased its position in Bristol-Myers Squibb (NYSE:BMY) by 3.3% during the second quarter, Holdings Channel reports. The fund owned 17,317 shares of the biopharmaceutical company’s stock after purchasing an additional 559 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Bristol-Myers Squibb were worth $719,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Davidson Investment Advisors raised its holdings in shares of Bristol-Myers Squibb by 1.7% during the second quarter. Davidson Investment Advisors now owns 274,542 shares of the biopharmaceutical company’s stock valued at $11,402,000 after buying an additional 4,631 shares during the last quarter. nVerses Capital LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth $349,000. Mizuho Markets Americas LLC grew its stake in shares of Bristol-Myers Squibb by 1,172.5% in the second quarter. Mizuho Markets Americas LLC now owns 2,799,600 shares of the biopharmaceutical company’s stock worth $116,267,000 after purchasing an additional 2,579,600 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 2.1% during the second quarter. Farther Finance Advisors LLC now owns 37,136 shares of the biopharmaceutical company’s stock valued at $1,534,000 after purchasing an additional 772 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Bristol-Myers Squibb by 15.1% in the second quarter. Van ECK Associates Corp now owns 9,152,206 shares of the biopharmaceutical company’s stock worth $380,091,000 after purchasing an additional 1,203,033 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Jefferies Financial Group upped their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Cantor Fitzgerald reiterated a “neutral” rating and set a $45.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Barclays upped their price objective on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Finally, TD Cowen lifted their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $54.67.

Bristol-Myers Squibb Stock Up 0.5 %

BMY opened at $49.95 on Tuesday. The business has a 50-day moving average of $45.32 and a 200-day moving average of $46.56. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.03. The company has a market capitalization of $101.25 billion, a PE ratio of -16.11, a price-to-earnings-growth ratio of 12.92 and a beta of 0.44. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.75 EPS. Equities research analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.80%. The ex-dividend date of this dividend was Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.